Biotech Banking Legend Jessica Chutter Joins PTC Board in Strategic Move

WARREN, N.J. – March 25, 2026 – PTC Therapeutics (NASDAQ: PTCT) has appointed Jessica Chutter, a titan of biotechnology investment banking, to its Board of Directors, a move that signals a significant strategic pivot for the rare disease-focused company. Ms. Chutter, who recently retired from a four-decade career at Morgan Stanley where she built its renowned biotechnology franchise, brings a formidable track record of financial stewardship and deal-making to a company navigating a complex landscape of commercial triumphs and pipeline challenges.

Her appointment is being interpreted by industry observers as a clear signal of PTC's ambitions. With a history of guiding companies through pivotal growth phases, Chutter's expertise in capital markets and strategic transactions is seen as a critical asset. "I have closely followed Jessica's illustrious career, and I am proud to welcome her to PTC's Board of Directors," said Michael Schmertzler, Chairman of the Board. "Jessica will play an integral role as the Board continues to work with the management team on charting the company's next stage of growth."

A Dealmaker's New Domain

Jessica Chutter is widely regarded as a pioneer who helped establish the very field of biotechnology investment banking. During her long tenure at Morgan Stanley, which culminated in her role as Chair of Biotechnology Investment Banking, she was involved in approximately $80 billion in capital raising and $85 billion in strategic transactions. Her portfolio includes landmark deals that shaped the modern biotech landscape, such as advising on Galapagos's $5.1 billion partnership with Gilead and facilitating major capital raises for companies like Moderna.

This deep financial acumen arrives at a crucial moment for PTC. The company boasts a strong balance sheet, ending 2025 with nearly $2 billion in cash and equivalents, bolstered by a recent $240 million upfront payment from monetizing its Evrysdi royalty stream. However, it also faces the high-stakes financial realities of biopharmaceutical development. The CEO of PTC Therapeutics, Matthew B. Klein, M.D., highlighted a pre-existing relationship, noting, "Jessica was a trusted advisor to PTC during her time at Morgan Stanley." This history suggests her integration into the board will be seamless, bringing her deep understanding of the company's financial structure and strategic goals directly into the boardroom.

Her reputation for "company-building" is particularly relevant. With PTC aiming to achieve cash flow breakeven in 2026, Chutter's experience in structuring deals, managing capital, and communicating with investors will be invaluable. Her appointment is a strategic move to leverage top-tier financial expertise to translate scientific innovation into sustainable commercial success and shareholder value.

Beyond the Balance Sheet: A Trend in Biotech Governance

Chutter's appointment is also emblematic of a broader industry trend: biopharmaceutical companies are increasingly recruiting seasoned financial architects to their boards. In a sector defined by high cash burn, long development timelines, and the binary risks of clinical trials, having an expert in capital markets and M&A at the highest level of governance is becoming less of a luxury and more of a necessity.

These financial experts provide more than just oversight; they offer strategic guidance on navigating public markets, securing non-dilutive funding, and executing the complex partnerships and acquisitions that fuel growth. Chutter’s move follows a pattern seen across the industry, where former investment bankers and financial executives are being tapped to provide a steady hand on the financial tiller.

For PTC, this means adding a board member whose perspective is forged by decades of analyzing what makes a biotech company successful from a financial and strategic standpoint. This experience is critical for a company with a diverse portfolio that includes blockbuster launches, promising but expensive late-stage trials, and recent regulatory setbacks. Dr. Klein emphasized this, stating, "her broad vision, extensive biotech experience and track record of successful company building will make her a valued Board member."

Fueling the Rare Disease Engine

Ms. Chutter joins PTC as the company stands at a pivotal juncture, balancing the extraordinary success of a new product with the inherent uncertainties of its pipeline. The company’s primary growth driver is Sephience (sepiapterin), a treatment for Phenylketonuria (PKU) that has had a phenomenal global launch. After its introduction in the second half of 2025, the drug generated $111 million in revenue, far exceeding expectations and positioning it as the foundation for PTC's goal of near-term profitability. Analysts see Sephience tapping into a market opportunity of approximately $1.2 billion.

This commercial success provides the financial firepower to advance a high-risk, high-reward pipeline. The centerpiece is Votoplam, a candidate for Huntington's Disease. PTC has aligned with the FDA on a Phase 3 trial set to begin in the first half of 2026, with the agency indicating openness to a potential Accelerated Approval pathway—a significant opportunity in a field with immense unmet need. Successfully funding and navigating this trial will be a major undertaking where Chutter's strategic financial input will be critical.

However, PTC's portfolio is not without its challenges. The company recently withdrew its U.S. application for Translarna for Duchenne Muscular Dystrophy after negative FDA feedback, a major setback that followed the non-renewal of its marketing authorization in Europe. Furthermore, its candidate for Friedreich's Ataxia, vatiquinone, will require an additional study before it can be resubmitted for FDA approval. These hurdles highlight the volatility of the rare disease space and the importance of disciplined capital allocation and strategic portfolio management.

In her own statement, Ms. Chutter acknowledged this dynamic, expressing that she has been "impressed with the transformation of PTC over the past few years into a strong and execution-oriented biotech company well positioned for future success." Her decision to join the board reflects a belief in the company's trajectory and its leadership. As she put it, "I look forward to working with Matt, Michael, and the rest of the PTC Board at this important time in the company's growth."